Elan Meltdown May End R&D Joint Ventures As Funding Vehicle For Biotech
The Elan market meltdown is likely to shut off the joint venture route as one avenue for struggling biotech companies to obtain capital
The Elan market meltdown is likely to shut off the joint venture route as one avenue for struggling biotech companies to obtain capital